Establishing local manufacturing in emerging markets

Boston Oncology is an innovative biogenerics company that focuses on the licensing, local development, manufacturing, and distribution of US-quality medicines across various therapeutic areas. The company operates a state-of-the-art manufacturing facility in Saudi Arabia, which is GMP certified and boasts an impressive annual vial capacity of over 30 million units. This facility is designed to deliver high-quality biogenerics quickly and reliably, ensuring that healthcare solutions are accessible and affordable in local markets. Boston Oncology emphasizes its commitment to global health standards while maintaining control over supply chains through strategic partnerships with leading pharmaceutical innovators.

The company’s approach is characterized by a strong alignment with the KSA Vision 2030, which underscores its mission-driven growth and dedication to serving community health. By leveraging its international presence and expertise, Boston Oncology aims to provide class-leading biogenerics that meet rigorous quality standards. The company’s focus on single-point-of-contact procurement simplifies the process for clients, enhancing efficiency and responsiveness in the healthcare supply chain. Overall, Boston Oncology is committed to redefining excellence in biogenerics, ensuring that the quality of healthcare is not dictated by wealth, status, or geography.

United States

Bold and nimble, Boston Oncology is an innovative biogenerics company redefining excellence in the licensing and local development, manufacturing and distribution of US- quality medicines – across therapeutic areas.

From our nerve center in Riyadh, we leverage the expertise, daring creativity, and unwavering determination of our international leadership team to provide customers with end-to-end, efficient, single-point-of-contact access to our diverse portfolio of world-class biogenerics.

We do this because lives depend on it.

Boston Oncology

Company Details